Page 34 - วารสารการแพทย์แผนไทย ปีที่ 20 ฉบับที่ 2 พฤษภาคม-สิงหาคม 2565

232 วารสารการแพทย์แผนไทยและการแพทย์ ทางเลือก ปีที่ 20 ฉบับที่ 2 พฤษภาคม-สิงหาคม 2565

Table 4 The median time to the onset of clinical improvement in the diclofenac and Justicia gendarussa Burm.f. spray
intervention groups.

Survival time (days) 95%CI Hazard ratio p-value
Diclofenac spray 3 3-4 1.182 0.447
Justicia gendarussa Burm.f. spray 3 2-4

† Survival analysis

the patients in DFS and JGS groups as a rescue and 8.3% of patients treated with JGS reported
medication were not statistically significant skin irritation. The incidence of this adverse
either (0.85 ± 2.18 vs 1.91 ± 4.52 tablets) (p = event was not significantly different between

0.149). the two groups (p > 0.05). No serious adverse
Regarding the safety of the study medica- event was detected in either group.
tions, 6.38% of participants treated with DFS

Figure 2 The patient global assessment results after a week of administering DFS and JGS.

Discussion meta-analysis of topical NSAIDs . The result
[12]
It was found in a previous study that of our study was consistent with the previous

topical NSAIDs, compared to a placebo, could study, which reports that following a 7-day
deliver 50% relief of pain and bring about the intervention, the VAS score of the pain of DFS
effect of treatment in 6-14 days, according to a provided reduced 61.05% while JGS 60.51%.